THE Australian and New Zealand Sarcoma Association (ANZSA) is urging the government to increase funding for sarcoma research, particularly for early detection and better treatment options.
At a Sarcoma Community Connection event in Brisbane today, ANZSA highlighted the challenges faced by those diagnosed with this rare cancer, which affects both soft tissue and bones.
Sarcoma impacts around 600 Australians and 150 New Zealanders annually, with a five-year survival rate of just 50-70%.
Prof Peter Steadman is an orthopaedic surgeon, and incoming President of the international sarcoma group hosting the conference, ISOLS, at the Brisbane Convention Centre with ANZSA.
He noted that sarcoma is especially concerning for young people, being the third most common cancer in children and adolescents.
"Early detection is crucial, yet it's incredibly difficult to diagnose," Steadman commented.
"We desperately need breakthroughs, and that starts with greater investment in research."
Despite sarcoma's significant impact, it remains one of the least funded cancers, with little progress in treatment over the past 40 years.
Sarah Cheung, Chairperson of ANZSA's Consumer Advisory Panel and a sarcoma survivor, emphasised, "it's shocking that sarcoma has not seen a breakthrough in decades".
"As a sarcoma survivor, I know how difficult the journey is."
Without increased resources and research, patients will continue to face poor outcomes, she stressed.
"We need to amplify awareness of sarcoma and ensure people understand the gravity of this disease," Cheung added.
"Early detection can save lives, but without proper funding, advancements will remain out of reach," she concluded. JG
The above article was sent to subscribers in Pharmacy Daily's issue from 10 Oct 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Oct 24
